IRIS
NOZZA, SILVIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.476
AS - Asia 3.279
NA - Nord America 2.505
SA - Sud America 745
AF - Africa 75
OC - Oceania 9
Totale 11.089
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 2.674
US - Stati Uniti d'America 2.364
SG - Singapore 1.156
CN - Cina 1.101
BR - Brasile 608
HK - Hong Kong 361
RO - Romania 340
VN - Vietnam 323
IT - Italia 315
SE - Svezia 274
DE - Germania 230
FR - Francia 179
GB - Regno Unito 130
FI - Finlandia 96
IN - India 79
AR - Argentina 72
CA - Canada 69
MX - Messico 57
PL - Polonia 57
ID - Indonesia 47
AT - Austria 43
BD - Bangladesh 41
NL - Olanda 33
ZA - Sudafrica 32
ES - Italia 29
IQ - Iraq 29
JP - Giappone 25
TR - Turchia 25
LT - Lituania 23
MA - Marocco 17
EC - Ecuador 16
UA - Ucraina 16
CO - Colombia 12
IE - Irlanda 12
PK - Pakistan 12
VE - Venezuela 11
PH - Filippine 10
AU - Australia 9
UZ - Uzbekistan 9
BE - Belgio 8
EG - Egitto 8
KZ - Kazakistan 8
SA - Arabia Saudita 8
AE - Emirati Arabi Uniti 7
CL - Cile 7
PY - Paraguay 7
UY - Uruguay 7
MY - Malesia 6
JO - Giordania 5
DO - Repubblica Dominicana 4
IL - Israele 4
KE - Kenya 4
RS - Serbia 4
AZ - Azerbaigian 3
HN - Honduras 3
NP - Nepal 3
PE - Perù 3
SI - Slovenia 3
TN - Tunisia 3
AL - Albania 2
CH - Svizzera 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
GH - Ghana 2
GT - Guatemala 2
IR - Iran 2
LB - Libano 2
NG - Nigeria 2
OM - Oman 2
PS - Palestinian Territory 2
SN - Senegal 2
SY - Repubblica araba siriana 2
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
CG - Congo 1
CY - Cipro 1
ET - Etiopia 1
GE - Georgia 1
GR - Grecia 1
GY - Guiana 1
JM - Giamaica 1
KG - Kirghizistan 1
KW - Kuwait 1
LK - Sri Lanka 1
LR - Liberia 1
MD - Moldavia 1
NI - Nicaragua 1
PA - Panama 1
QA - Qatar 1
Totale 11.089
Salva come PNG Salva come JPEG
Città #
Singapore 599
Moscow 529
Hong Kong 356
Dallas 349
Ashburn 346
San Jose 274
Shanghai 191
Beijing 168
Hefei 152
New York 151
Lauterbourg 135
Ho Chi Minh City 105
Los Angeles 103
Munich 98
Milan 87
Lawrence 79
Princeton 79
São Paulo 68
Hanoi 61
Orem 52
Helsinki 47
Warsaw 45
Denver 44
Boardman 42
Nuremberg 42
London 36
Santa Clara 34
Cesano Boscone 33
Montreal 32
Turku 31
Chennai 30
Guangzhou 30
Stockholm 29
Poplar 26
Brooklyn 25
Frankfurt am Main 25
St Petersburg 24
Tokyo 24
Falkenstein 23
Gatchina 23
Amsterdam 22
Seattle 22
Atlanta 21
Vienna 21
Da Nang 20
Council Bluffs 19
Houston 19
Johannesburg 19
Manchester 19
Rio de Janeiro 19
Mexico City 18
Phoenix 17
Shenzhen 17
Haiphong 15
Lappeenranta 15
Toronto 15
Ankara 14
Brasília 14
Rome 14
Yekaterinburg 14
Baghdad 13
Belo Horizonte 13
Boston 12
Chicago 12
Perm 12
Tianjin 12
Dublin 11
Jakarta 11
Nanjing 11
Pune 11
Querétaro 11
Barnet 10
Mumbai 10
Biên Hòa 9
New Delhi 9
Tashkent 9
Brussels 8
Charlotte 8
Dhaka 8
Hải Dương 8
Nizhniy Novgorod 8
Porto Alegre 8
Romagnano Sesia 8
San Francisco 8
Turin 8
Cape Town 7
Columbus 7
Goiânia 7
Guayaquil 7
Paris 7
Bogotá 6
Busto Arsizio 6
Curitiba 6
Fortaleza 6
Guarulhos 6
Naples 6
Pouso Alegre 6
Quito 6
Riyadh 6
Salvador 6
Totale 5.324
Salva come PNG Salva come JPEG
Nome #
The propensity for long-acting cabotegravir and rilpivirine every 2 months among HIV-infected people eligible for treatment 249
Monkeypox in a patient with undifferentiated connective tissue disease 249
Viral bloodstream detection in mpox patients: An observational multicentric study 232
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 180
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 166
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study 142
A case of breakthrough mpox infection in an individual non-responder to MVA-BN vaccination 130
Human Monkeypox Experience in a Tertiary Level Hospital in Milan, Italy, between May and October 2022: Epidemiological Features and Clinical Characteristics 126
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (Scientific Reports, (2020), 10, 1, (21291), 10.1038/s41598-020-78039-1) 124
Characteristics of HIV pre-exposure prophylaxis users at first PrEP counselling visit: the CSL-PrEP cohort 124
Allogeneic bone marrow transplantation in HIV people with hematological malignancies: Post-transplant cyclophosphamide to overcome the HLA-matching barrier 121
HIV viral load monitoring during monkeypox virus infection among people with HIV 116
Meningococcus B Vaccination Effectiveness Against Neisseria gonorrhoeae Infection in People Living With HIV: A Case-Control Study 115
Mpox Outbreak 2022: A Comparative Analysis of the Characteristics of Individuals Receiving MVA-BN Vaccination and People Diagnosed with Mpox Infection in Milan, Italy 113
Analysis of the faecal microbiome during analytical treatment interruption in people with chronic HIV infection and long-lasting virological suppression (APACHE study) 112
Analytical treatment interruption in chronic HIV-1 infection: Time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study) 109
Breakthrough monkeypox infection among individuals previously immunized with smallpox or monkeypox vaccination 108
Association of high-risk sexual behaviours with sexually transmitted infections among men who have sex with men living with HIV 107
Trends of Antimicrobial Susceptibility of Neisseria gonorrhoeae Isolates between 2012 and 2023: Results from an Open Italian Cohort 105
High Propensity to Switch to Long-acting Injectable HIV PrEP with Cabotegravir in a Cohort of Oral PrEP Experienced Men who Have Sex with Men in Italy 103
Beyond stigma: Monkeypox infection in a 27-year-old woman 102
Viral Hepatitis and Human Papillomavirus Vaccination during HIV Pre-Exposure Prophylaxis: Factors Associated with Missed Vaccination 101
Implementation of recombinant anti-herpes zoster vaccination in people living with HIV: a single-center experience 101
Monkeypox infection among men who have sex with men: PCR testing on seminal fluids 99
Isolated monkeypox proctitis among men who have sex with men 99
Monkeypox infection in a hemopoietic stem cell and heart transplant recipient 99
Antiretroviral therapy in geriatric HIV patients: The GEPPO cohort study 99
Failure of on-demand pre-exposure prophylaxis: the risk of HIV drug resistance 99
Sexually transmitted infections in men who have sex with men with tenofovir/emtricitabine- or cabotegravir-resistant HIV 99
Beneficial effects of cART initiated during primary and chronic HIV-1 infection on immunoglobulin-expression of memory B-cell subsets 98
Persistent ocular mpox infection in an immunocompetent individual 96
A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study 96
Enhanced immunological recovery with early start of antiretroviral therapy during acute or early HIV infection–results of Italian network of acute HIV infection (Inaction) retrospective study 95
Prior Neisseria meningitidis (Nm) proctitis does not prevent Neisseria gonorrhoeae (Ng) proctitis among men who have sex with men (MSM) 93
One Year of Long-Acting Cabotegravir and Rilpivirine in People With Human Immunodeficiency Virus and Long Exposure to Antiretroviral Therapy: Data From the SCohoLART Study 93
HIV-DNA undetectability during chronic HIV infection: Frequency and predictive factors 93
Anti-Tat immunity defines CD4 + T-cell dynamics in people living with HIV on long-term cART 92
Tick-borne encephalitis seroprevalence in northern Italy: a cross-sectional study on a randomly selected population 91
Mpox neutralising antibodies at 6 months from mpox infection or MVA-BN vaccination: a comparative analysis 90
Rectal Lymphogranuloma venereum among Men who Have Sex with Men: 7 versus 21 Days Doxycycline Effectiveness 89
Activating Killer Immunoglobulin Receptors and HLA-C: A successful combination providing HIV-1 control 89
Increasing incidence and prevalence of metabolic syndrome in people living with HIV during the COVID-19 pandemic 88
Sexually Transmitted Enteric Infections in Men Who Have Sex With Men Living With HIV Over 8 Years of Follow-up 88
HIV-NAAT use for early detection of HIV infection among high-risk men who have sex with men in Italy 88
Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice 87
A new antigen scanning strategy for monitoring HIV-1 specific T-cell immune responses 87
Antibiotic resistance among sexually transmitted infections: perspectives from clinical practice 86
Monkeypox and pan-resistant Campylobacter spp infection in Entamoeba histolytica and Chlamydia trachomatis re-infection in a man who have sex with men 86
Brief Report: New HIV Diagnoses in PrEP-Experienced and PrEP-Naive Persons in the ICONA Cohort 86
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 85
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort 84
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 84
Viral hepatitis and human papillomavirus vaccination during pre-exposure prophylaxis: factors associated with missed vaccination 83
Two individuals with potential monkeypox virus reinfection 82
Role of multi-site sampling in the diagnosis of human Monkeypox 80
Late positivization of oropharyngeal, plasma, anal, semen, and urine specimens which tested negative at the time of mpox diagnosis 80
Proctitis and prostatitis by Neisseria meningitidis among MSM: A case series 80
VIRO-immunological outcomes after 13-valent pneumococcal vaccination in HIV-1-infected individuals on stable virological suppression 80
Early Diagnosis and Linkage to Care: an Experience over 14 years of Point of Care Rapid HIV Testing 78
Evaluation of HIV transmission clusters among natives and foreigners living in Italy 77
Real-life use of cidofovir for the treatment of severe monkeypox cases 76
Doravirine associated with greater LDL cholesterol reduction in people with HIV switching antiretroviral regimens 75
Evaluation of analytical performance of the STANDARDTM M10 MPX/OPX assay for the simultaneous DNA detection and clade attribution of Monkeypox virus 73
An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project. 72
Pharmacokinetics of the raltegravir/maraviroc/etravirine combination 72
Clinical and laboratory predictors of mpox severity and duration: an Italian multicentre cohort study (mpox-Icona) 71
Monotherapy with atazanavir as a simplification strategy: results from an observational study. 71
B-cell subset alterations and correlated factors in HIV-1 infection 71
Ageing with HIV: a multidisciplinary review 70
Estimated glomerular filtration rate trajectories in HIV-infected subjects treated with different ritonavir-boosted protease inhibitors and tenofovir disoproxil fumarate or abacavir 70
Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression 70
Mpox in people with past infection or a complete vaccination course: a global case series 69
Prevalence and Risk Factors of Anal HPV Infection in MSM Living With HIV: Identifying the Target Groups to Prioritize for Immunization 69
Vaccines against Emerging Sexually Transmitted Infections: Current Preventive Tools and Future Perspectives 68
Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen 68
Differential dynamics of Epstein-Barr virus in individuals infected with human immunodeficiency virus-1 receiving intermittent interleukin-2 and antiretroviral therapy 67
Incidence and Predictors of Serological Treatment Response in Early and Late Syphilis Among People Living With HIV 67
Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen 67
Multidrug-resistant Mycoplasma genitalium urethritis: successful eradication with sequential therapy 66
Dynamics of adaptive and innate immunity inpatients treated during primary human immunodeficiency virus infection: Results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial 66
Awareness and perception of accuracy of the Undetectable=Untransmittable message (U=U) in Italy: results from a survey among PLWHA, infectious-diseases physicians and people having unprotected sex 65
Maraviroc 150mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study 65
Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption 64
Mpox Virus: Control of In-Hospital Occupational Transmission Experience from a Tertiary Level Hospital in Milan, Italy 63
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients 63
Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine 62
Unified European support framework to sustain the HIV cascade of care for people living with HIV including in displaced populations of war-struck Ukraine 61
Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients 59
Immune recovery and T cell subset analysis during effective treatment with maraviroc 59
Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy 58
Exercise ECG for coronary artery disease screening in people living with HIV: The cordis STUDY 58
Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022 57
Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection 57
Rapid improvement of severe Mpox lesions with oral tecovirimat 56
Maraviroc in addition to cART during primary HIV infection: Results from MAIN randomized clinical trial and 96-weeks follow-up 56
Presence of multiple genotypes in subjects with HPV-16 infection is highly associated with anal squamous intraepithelial lesions in HIV-1 infected males 56
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 55
The Less Drugs Regimens (LDRs) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection. 55
Performance of commonly used genotypic assays and comparison with phenotypic assays of HIV-1 coreceptor tropism in acutely HIV-1-infected patients 55
HIV-1-mediated insertional activation of STAT5B and BACH2 trigger viral reservoir in T regulatory cells 55
Totale 9.010
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.310
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 55.310
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211 0 0 0 0 0 0 0 0 0 0 1 0
2021/202273 0 0 0 20 7 9 3 6 4 11 3 10
2022/2023469 178 99 20 2 1 42 48 56 9 5 4 5
2023/2024559 9 19 99 48 64 125 21 58 1 15 30 70
2024/20252.693 196 35 75 78 123 224 712 316 267 201 166 300
2025/20267.506 606 530 474 1.060 649 276 646 652 2.224 389 0 0
Totale 11.374